IE 11 is not supported. For an optimal experience visit our site on another browser.

Vivakor Announces Acquisition Strategy for Its VivaSight and VivaSlices Divisions

CORALVILLE, Iowa, Sept. 27, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) today announced that due to the increased interest in the Company's technologies, the Company is looking to structure acquisition partners for its technologies which will allow for the investment needed to fully commercialize VivaSlices and VivaSight technologies.
/ Source: GlobeNewswire

CORALVILLE, Iowa, Sept. 27, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) today announced that due to the increased interest in the Company's technologies, the Company is looking to structure acquisition partners for its technologies which will allow for the investment needed to fully commercialize VivaSlices and VivaSight technologies.

As our Digital Photo Refractor research grant has completed, the market indications and applications of our technology have expanded.  Not only has the demand for our vision screening technology expanded to potentially include all ages, the demand for international vision screening has opened potential distribution outlets for VivaSight products that the Company is striving to take to market through its fund raising efforts.

VivaSlices, MRI enhancement software, continues to make strides as the company seeks financing to ensure the technology will be ready for new regulations that take effect next year.  The Company has sought out commercialization and finance partners for VivaSlices technology and looks forward to completing such efforts.

Management feels that the current stock price and company market capitalization is undervalued and the outlook for current product sales and pre-orders for VivaSight and VivaSlices technologies surpass current market values.  As financing objectives are completed, management believes the fundamentals of the Company will insure Vivakor's long term strategy of extending the length and quality of life through detection and prevention.

About Vivakor, Inc.

Vivakor™ is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life.  More information can be found about Vivakor at .

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential.  Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions.  These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements.  Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

CONTACT: Vivakor Investor Relations (888) 648-8485